The Latest Cardiac and Vascular News
Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that a manuscript detailing the baseline characteristics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase […]
First Report of TransAeris® Diaphragm Pacer (DP) in High Risk Cardiac Surgeries under FDA Emergency Use Authorization OBERLIN, Ohio, Oct. 1, 2020 /PRNewswire/ — Synapse Biomedical, Inc®. (www.synapsebiomedical.com) announced today that surgeons at University Hospitals Cleveland Medical Center have improved the prognosis of several cardiac patients after the use of TransAeris DP […]
DUBLIN, Oct. 1, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ DES. The Resolute Onyx DES […]
TEL AVIV, Israel, Oct. 1, 2020 /PRNewswire/ — Vascular Graft Solutions Ltd. (VGS), an Israel-based innovative commercial-stage medical device company, announced today that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation for VEST™, an external stent for vein grafts in coronary artery bypass surgery. VEST™ was proven to mitigate […]
WEST PALM BEACH, Fla., Oct. 1, 2020 /PRNewswire/ — Prince Sultan Cardiac Center Al Hassa (PSCCH) (https://www.pscch.med.sa/portal/en/), one of the premier cardiac centers in Saudi Arabia, is the first hospital in the Middle East to be awarded Global Healthcare Accreditation’s Certification of Conformance with COVID-19 Guidelines for Medical Travel Programs (https://www.globalhealthcareaccreditation.com/certification-of-conformance-with-gha-covid-19-guidelines-for-medical-travel-programs). The Global Healthcare Accreditation (GHA) Program for Medical Travel […]
BOSTON, Oct. 1, 2020 /PRNewswire/ — Dyad Medical, Inc., a groundbreaking medical image analysis platform delivering cloud-based artificial intelligence (AI)-based analysis, announced after just 90 days, the closing of its oversubscribed Series Seed funding round led by The Unofficial Syndicate, with participation by Social Starts L.P., and local angel investors. Along with grants […]
Study Opens a New, Additional Area of Development for Istaroxime WARRINGTON, Pa., Oct. 1, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 […]
Builds upon health system’s leadership in cardiology with its newly opened Women’s Heart Center and special Cardio-Oncology Program MOUNTAIN VIEW, Calif., Oct. 1, 2020 /PRNewswire/ — El Camino Health has been recognized with the Transcatheter Valve Certification from the American College of Cardiology (ACC), acknowledging its exceptional program, physician leadership, quality patient outcomes and […]
OAKLAND, Calif.–(BUSINESS WIRE)–Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that a poster highlighting the ability of a Dascena machine learning algorithm to provide earlier identification of acute coronary syndrome (ACS) is being presented during the Heart […]
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI® (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults […]
